Halozyme Therapeutics, Inc.
HALO
$63.65
-$1.48-2.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.55% | 31.19% | 34.97% | 25.65% | 22.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.55% | 31.19% | 34.97% | 25.65% | 22.44% |
| Cost of Revenue | 39.42% | 9.48% | 5.21% | -10.37% | -24.96% |
| Gross Profit | 37.09% | 37.48% | 44.81% | 40.11% | 45.16% |
| SG&A Expenses | 25.31% | 15.11% | 16.52% | 9.94% | 3.45% |
| Depreciation & Amortization | 7.90% | 0.00% | -0.11% | -0.21% | -0.31% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.11% | 7.46% | 5.82% | 1.18% | -5.18% |
| Operating Income | 48.02% | 54.59% | 68.73% | 56.48% | 62.16% |
| Income Before Tax | -16.20% | 55.37% | 66.09% | 54.27% | 59.94% |
| Income Tax Expenses | 32.68% | 71.69% | 69.81% | 63.08% | 69.39% |
| Earnings from Continuing Operations | -28.64% | 51.73% | 65.22% | 52.25% | 57.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.64% | 51.73% | 65.22% | 52.25% | 57.71% |
| EBIT | 48.02% | 54.59% | 68.73% | 56.48% | 62.16% |
| EBITDA | 43.18% | 47.07% | 57.78% | 46.86% | 50.41% |
| EPS Basic | -25.45% | 59.02% | 71.10% | 57.10% | 63.48% |
| Normalized Basic EPS | 57.19% | 63.55% | 77.48% | 64.59% | 71.40% |
| EPS Diluted | -27.54% | 57.13% | 69.17% | 55.18% | 62.32% |
| Normalized Diluted EPS | 56.91% | 61.90% | 76.05% | 63.33% | 70.67% |
| Average Basic Shares Outstanding | -5.49% | -4.27% | -3.35% | -3.10% | -3.88% |
| Average Diluted Shares Outstanding | -5.11% | -3.31% | -2.54% | -2.38% | -3.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |